318 related articles for article (PubMed ID: 35693346)
1. Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies.
Just MK; Gram H; Theologidis V; Jensen PH; Nilsson KPR; Lindgren M; Knudsen K; Borghammer P; Van Den Berge N
Front Aging Neurosci; 2022; 14():907293. PubMed ID: 35693346
[TBL] [Abstract][Full Text] [Related]
2. ⍺-Synuclein Structural Diversity and the Cellular Environment in ⍺-Synuclein Transmission Models and Humans.
Peelaerts W; Baekelandt V
Neurotherapeutics; 2023 Jan; 20(1):67-82. PubMed ID: 37052776
[TBL] [Abstract][Full Text] [Related]
3. The promise of amplification assays for accurate early detection of α-synucleinopathies: A review.
Kurapova R; Chouliaras L; O'Brien JT
Exp Gerontol; 2022 Aug; 165():111842. PubMed ID: 35623540
[TBL] [Abstract][Full Text] [Related]
4. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
Peelaerts W; Bousset L; Baekelandt V; Melki R
Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
[TBL] [Abstract][Full Text] [Related]
5. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
[TBL] [Abstract][Full Text] [Related]
6. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies.
Moors TE; Mona D; Luehe S; Duran-Pacheco G; Spycher L; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Dernick G; van de Berg WDJ; Britschgi M
Acta Neuropathol Commun; 2022 Jun; 10(1):82. PubMed ID: 35659116
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein Conformational Strains as Drivers of Phenotypic Heterogeneity in Neurodegenerative Diseases.
So RWL; Watts JC
J Mol Biol; 2023 Jun; 435(12):168011. PubMed ID: 36792008
[TBL] [Abstract][Full Text] [Related]
8. [Neuroprotective treatment of idiopathic, genetic and atypical Parkinson's disease with alpha-synuclein-Pathology].
Levin J; Nübling G; Giese A; Janzen A; Oertel W
Nervenarzt; 2021 Dec; 92(12):1249-1259. PubMed ID: 34735584
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder.
Stefani A; Iranzo A; Holzknecht E; Perra D; Bongianni M; Gaig C; Heim B; Serradell M; Sacchetto L; Garrido A; Capaldi S; Sánchez-Gómez A; Cecchini MP; Mariotto S; Ferrari S; Fiorini M; Schmutzhard J; Cocchiara P; Vilaseca I; Brozzetti L; Monaco S; Jose Marti M; Seppi K; Tolosa E; Santamaria J; Högl B; Poewe W; Zanusso G;
Brain; 2021 May; 144(4):1118-1126. PubMed ID: 33855335
[TBL] [Abstract][Full Text] [Related]
10. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
11. Seeding variability of different alpha synuclein strains in synucleinopathies.
Candelise N; Schmitz M; Llorens F; Villar-Piqué A; Cramm M; Thom T; da Silva Correia SM; da Cunha JEG; Möbius W; Outeiro TF; Álvarez VG; Banchelli M; D'Andrea C; de Angelis M; Zafar S; Rabano A; Matteini P; Zerr I
Ann Neurol; 2019 May; 85(5):691-703. PubMed ID: 30805957
[TBL] [Abstract][Full Text] [Related]
12. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.
Visanji NP; Lang AE; Kovacs GG
Transl Neurodegener; 2019; 8():28. PubMed ID: 31508228
[TBL] [Abstract][Full Text] [Related]
13. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein Seeding Assay Using RT-QuIC.
Okuzumi A; Hatano T; Fukuhara T; Ueno S; Nukina N; Imai Y; Hattori N
Methods Mol Biol; 2021; 2322():3-16. PubMed ID: 34043187
[TBL] [Abstract][Full Text] [Related]
15. RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein.
Srivastava A; Alam P; Caughey B
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454165
[TBL] [Abstract][Full Text] [Related]
16. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
Lashuel HA
Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
[TBL] [Abstract][Full Text] [Related]
17. Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies.
Brás IC; Outeiro TF
Cells; 2021 Feb; 10(2):. PubMed ID: 33673034
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of alpha-synuclein toxicity: An update and outlook.
Brás IC; Xylaki M; Outeiro TF
Prog Brain Res; 2020; 252():91-129. PubMed ID: 32247376
[TBL] [Abstract][Full Text] [Related]
19. Protein trapping leads to altered synaptic proteostasis in synucleinopathies.
Santos PI; Outeiro TF
FEBS J; 2020 Dec; 287(24):5294-5303. PubMed ID: 32400966
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
Bellomo G; De Luca CMG; Paoletti FP; Gaetani L; Moda F; Parnetti L
Neurology; 2022 Aug; 99(5):195-205. PubMed ID: 35914941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
